Outcomes associated with tocilizumab with or without corticosteroid versus dexamethasone for treatment of patients with severe to critical COVID-19 pneumonia

• Main Authors: Hajar AlQahtani (Author), Sara AlBilal (Author), Ebrahim Mahmoud (Author), Omar Aldibasi (Author), Ahmad Alharbi (Author), Nour Shamas (Author), Abdulrahman Alsaedy (Author), Kenana Owaidah (Author), Fulwah Yahya Alqahtani (Author), Fadilah Sfouq Aleanizy (Author), Hatim Arishi (Author), Saleem Baharoon (Author), Mohammad Bosaeed (Author)
• Format: Book
• Published: Elsevier, 2022-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Introduction: Immunomodulators, including dexamethasone (DEX), have been recommended by the Infectious Disease Society of America (IDSA) to treat moderate, severe, and critical COVID-19. Tocilizumab (TCZ) was added to the treatment recommendations based on recent data from two large randomized contr...